Celldex Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Celldex Therapeutics, Inc. (CLDX) develops novel antibody-based immunotherapies targeting mast cell-mediated inflammatory, allergic, and autoimmune diseases. The company's lead product candidate, barzolvolimab (CDX-0159), a humanized monoclonal antibody KIT antagonist, advances in Phase 3 trials for chronic spontaneous urticaria and Phase 2 trials for cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis; CDX-622, a TSLP/SCF bispecific antibody, progresses in Phase 1 healthy volunteer studies to deplete mast cells and inhibit Type 2 inflammation in broader inflammatory and fibrotic disorders. Founded in 1983 and headquartered in Hampton, New Jersey, Celldex operates primarily in the United States with a focus on clinical-stage biopharmaceutical development for immunology indications and targets patients with severe mast cell-driven conditions. Recent developments include positive Phase 3 data for barzolvolimab reinforcing its pipeline-in-a-product potential, a proposed public offering of common stock to fund ongoing trials, and third quarter 2025 financial results highlighting pipeline advancement amid strategic collaborations for commercialization support.
Company News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
California State Teachers Retirement System Acquires 21,233 Shares of Celldex Therapeutics, Inc. $CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex to stop skin disease study after trial setback
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Announces Planned Transition of Chief Financial Officer
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Reports First Quarter Financial Results and Provides Corporate Update
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment